Epratuzumab for the treatment of systemic lupus erythematosus.

Geh, Daniel; Gordon, Caroline

Geh, Daniel; Gordon, Caroline.

Affiliation

Geh D; a Rheumatology Department , City Hospital, Sandwell and West Birmingham Hospitals NHS Trust , Birmingham , UK.
Gordon C; b University of Birmingham Research Labs , University Hospitals Birmingham NHS Foundation Trust , Birmingham , UK.

Expert Rev Clin Immunol ; 14(4): 245-258, 2018 04.

Article in En | MEDLINE | ID: mdl-29542345

Subject(s)

Antibodies, Monoclonal, Humanized/therapeutic use; B-Lymphocytes/immunology; Lupus Erythematosus, Systemic/drug therapy; Lupus Erythematosus, Systemic/immunology; Sialic Acid Binding Ig-like Lectin 2/antagonists & inhibitors; Antibodies, Monoclonal, Humanized/pharmacokinetics; B-Lymphocytes/pathology; Humans; Lupus Erythematosus, Systemic/pathology; Randomized Controlled Trials as Topic; Sialic Acid Binding Ig-like Lectin 2/immunology

Key words

B cell modulation; BICLA; BILAG; CD22; SLEDAI-2K; Sjogren's syndrome; disease activity; epratuzumab; lupus; monoclonal antibody; outcome; response; treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: B-Lymphocytes / Sialic Acid Binding Ig-like Lectin 2 / Antibodies, Monoclonal, Humanized / Lupus Erythematosus, Systemic Type of study: Clinical_trials Limits: Humans Language: En Year: 2018 Type: Article

Fulltext

XML

PubMed Links

Search on Google